Led by Abigail Brus, VP, Operations and Project Management, the Seattle laboratory is a dynamic, insight-driven workplace where our expert scientists generate an extensive biomarker assay portfolio encompassing metabolic and lipid biomarkers, safety markers such as the FDA-approved acute kidney injury (AKI) panel and a broad range of immunology and oncology markers.
We also have substantial expertise in bioanalytical testing, pharmacokinetic (PK), and neutralizing antibody assays (nAb). The laboratory is a 26,000 square foot facility, with an expansion to be completed in late 2021. It undertakes CAP/CLIA on-site inspections every two years (most recently 2021) and has undergone several FDA audits.
Setting a standard of consistent excellence and quality deliverables for over 15 years, the Seattle laboratory has produced an enormous body of industry-leading work: 1,500 individual projects (including over 450 CAP/CLIA) and over 680 compound identifications.
Certifications: CAP/CLIA, NYDOH, and GLP/GCP standards-bioanalytical.